RE:RE:RE:RE:RE:RE:TODAY's VOLUME Hi SanFran.
You make good points. I recall that the comment about being(not being) on the radar screen of senior execs at BP was something to the effect of.....it is very difficult to get the attention of execs at BPs... and it was made by Don to a question from an attendee at one of the corporate updates in the past year. But you are correct. I need to go back and get the exact reference.
Agreed also that if serious negotiations were going on with BP there would be a 100% intent to complete confidentially. However, as an example of how it works in the real world, the share price began to ramp up long before there was any public information available about the Hepalink plans.
Of course there will not be a BILLBOARD ON THE ROAD.
My personal view is that there is alot going on behind the scenes in terms of business strategy, partnerships and financing and I have 100% confidence this will remain an ongoing business.
Given the scientific developments since July 2013 and prior to that I am sure that AZ, Pfizer, etc have RVX and Zenith on their radar. It really is a question of how they are interpreting this new science and how far they believe RVX/Zen are along this path. Don always states that RVX has an 8 year lead with regards to apabetalone and I believe it purely from a clinical trial perspective just because of the time to do trials.
SF, good feedback. Thanks.
Toinv